Aptamer Group to host webinar and Q&A session for investors

Aptamer Group plc (LON: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, has announced that Dr Arron Tolley, Chief Executive Officer and Dr David Bunka, Chief Scientific Officer will be hosting a webinar on Thursday, 12 December 2024 at 6.00 pm (GMT).

The webinar will provide investors with a valuable opportunity to interact with Aptamer Group and gain insights into recent announcements.

There will be a Q&A session for investors after the presentation and questions can be submitted pre-event as part of the registration process.

You can register for the event by using the following link:

https://www.turnerpope.com/register/

We are delighted to announce that the webinar will be chaired by experienced news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com) and hosted by the Company’s broker, Turner Pope Investments.

Share on:

You might also enjoy reading Aptamer signs contract with Metir for Cryptosporidium detection binders

Written by: Amilia Stone

Latest Company News

Aptamer Group secures £270k in new orders and first cash licensing receipts

January 29, 2026

Aptamer Group plc has announced £190,000 in new fee-for-service Optimer® orders and £80,000 in cash licensing receipts, including its first payment from a hot-start PCR licence.

Aptamer reports 27% revenue growth and signs multiple licensing deals in H1 FY26

January 7, 2026

Aptamer Group reported unaudited revenue of £0.83 million for the six months to 31 December 2025, a 27% increase year on year, supported by strong fee-for-service demand and the signing of multiple licensing agreements.

Aptamer Group signs first licensing deal with Twist Bioscience

December 16, 2025

Aptamer Group has entered into its first licensing agreement with Twist Bioscience, granting a non-exclusive licence for the use of an Optimer® binder in hot-start PCR and next-generation sequencing products.

Aptamer Group AGM statement highlights contract wins and growing order book

November 27, 2025

Aptamer Group is holding its AGM today in York, where the Chairman will outline continued commercial progress, recent contract wins with major pharmaceutical companies, and an FY26 order book of £1.95 million.

Aptamer Group secures £192k contracts with global pharma, boosting FY26 order book to £1.95m

November 14, 2025

Aptamer Group announced two new contracts worth £192,000, including a fourth engagement with a top five global pharmaceutical company and a new deal targeting acute myeloid leukaemia.

Aptamer Group reports strong FY2025 growth and expands Optimer® portfolio

November 3, 2025

Aptamer Group delivered strong progress in FY2025, achieving a 40% revenue increase and expanding its portfolio of licensable Optimer® assets from four to eleven.